Black Hawk Acquisition Corporation Reports Decrease in Quarterly Net Income Amid Strategic Business Combination Plans

Black Hawk Acquisition Corporation has reported its financial results for the three and nine months ended August 31, 2025, revealing a net income of $154,401 for the quarter, a decrease from $883,767 in the same period last year. For the nine-month period, the company recorded a net income of $1,333,322, compared to $1,164,002 in the prior year. The decline in quarterly net income is attributed to a significant increase in general and administrative expenses, which rose to $311,265 from $54,903 year-over-year. The company also reported interest income of $494,562 for the quarter, down from $968,670 in the previous year, reflecting a decrease in the interest earned on investments held in the Trust Account.

The financial position of Black Hawk has changed markedly since the previous fiscal period. As of August 31, 2025, total assets stood at $23,341,102, a substantial decrease from $72,143,335 reported on November 30, 2024. This decline is primarily due to a reduction in investments held in the Trust Account, which fell to $23,296,572 from $71,829,264. The company’s liabilities also increased, with total current liabilities rising to $946,168 from $70,978, largely due to accrued offering costs and a convertible note issued to a related party.

Strategically, Black Hawk has made significant moves towards completing a business combination. On April 26, 2025, the company entered into a Business Combination Agreement with Vesicor Therapeutics, Inc., a biotechnology firm focused on cancer therapeutics. This agreement is expected to result in Vesicor becoming a wholly owned subsidiary of Black Hawk, with the transaction valuing Vesicor at a pre-money equity value of $70 million. The business combination is anticipated to close in the fourth quarter of 2025, subject to regulatory approvals and shareholder votes.

Operationally, Black Hawk has seen a reduction in its public shareholder base, with 4,775,923 public ordinary shares redeemed during the recent Extraordinary General Meeting, resulting in approximately $51 million being paid out from the Trust Account. Following these redemptions, approximately $22.7 million remains in the Trust Account, with 2,124,077 public ordinary shares still issued and outstanding. The company has also extended its business combination deadline to December 22, 2026, allowing for additional time to finalize the merger with Vesicor.

Looking ahead, Black Hawk faces challenges regarding its liquidity, with only $15,000 in cash and a working capital deficit of $901,638 as of August 31, 2025. The company has indicated that it will require additional capital to meet its operational needs and pursue its business combination plans. Management has expressed substantial doubt about the company's ability to continue as a going concern if it cannot complete the business combination within the designated timeframe. The financial statements do not include adjustments that might result from this uncertainty, highlighting the critical nature of the upcoming merger and the need for effective capital management.